Cover Image
市場調查報告書

惡病質:開發中產品分析

Cachexia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192512
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
惡病質:開發中產品分析 Cachexia - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 42 Pages
簡介

惡病質常見於包含第一型糖尿病的慢性疾病,多發性硬化症,HIV,癌症,及隨著高齡化的「發育障礙」症候群患者身上,會有劇烈體重減輕及肌肉萎縮。症狀有無法控制地體重減輕、肌肉骨骼的消耗、食欲不振、QOL(生活品質)低落等。治療方法有使用飲食療法、營養補充品、運動及投藥療法等。

本報告涵括全球惡病質治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

惡病質概要

治療藥的開發

  • 惡病質開發中產品:概要
  • 開發中的治療藥 - 各企業
  • 開發中的治療藥 - 各大學·研究機關
  • 開發中的產品 - 各企業
  • 開發中的產品 - 各大學·研究機關

惡病質:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

惡病質:開發治療藥的企業

  • Aphios Corp
  • GlaxoSmithKline Plc
  • MYOS RENS Technology Inc
  • Novartis AG
  • TEIJIN FIBERS製藥
  • VBS Pharmaceuticals

藥物簡介

  • 產品概要
  • 作用機制
  • R&D的進展

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9696IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia - Pipeline Review, H2 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape.

Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated "failure to thrive" syndrome. Symptoms include involuntary (unintentional) weight loss, skeletal muscle wasting, anorexia/loss of appetite, lowered quality of life. Treatment includes diet, nutritional supplements, exercise and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cachexia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 5, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Cachexia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cachexia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Cachexia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cachexia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cachexia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cachexia (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cachexia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cachexia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cachexia - Overview
    • Cachexia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cachexia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cachexia - Companies Involved in Therapeutics Development
    • Aphios Corp
    • Connexios Life Sciences Pvt Ltd
    • GlaxoSmithKline Plc
    • India Globalization Capital, Inc.
    • MYOS RENS Technology Inc
    • Teijin Pharma Ltd
    • Vascular BioSciences
    • Cachexia - Drug Profiles
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1889 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAR Peptide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNX-013B2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2881078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IGC-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEISARM-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cachexia - Dormant Projects
  • Cachexia - Discontinued Products
  • Cachexia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cachexia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cachexia - Pipeline by Aphios Corp, H2 2017
  • Cachexia - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
  • Cachexia - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Cachexia - Pipeline by India Globalization Capital, Inc., H2 2017
  • Cachexia - Pipeline by MYOS RENS Technology Inc, H2 2017
  • Cachexia - Pipeline by Teijin Pharma Ltd, H2 2017
  • Cachexia - Pipeline by Vascular BioSciences, H2 2017
  • Cachexia - Dormant Projects, H2 2017
  • Cachexia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cachexia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top